We are live on ! Find out more
LEXX icon

Lexaria Bioscience
LEXX

16 hedge funds and large institutions have $1.68M invested in Lexaria Bioscience in 2022 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 4 increasing their positions, 5 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

2.12% more ownership

Funds ownership: 9.44% → 11.56% (+2.1%)

1% more capital invested

Capital invested by funds: $1.67M → $1.68M (+$10K)

0% more funds holding

Funds holding: 16 → 16 (0)

0% more first-time investments, than exits

New positions opened: 3 | Existing positions closed: 3

20% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 5

Holders
16
Holders Change
–
Holders Change %
0%
% of All Funds
0.28%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
4
Reduced
5
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
ICM
Invenomic Capital Management
Massachusetts
+$307K
2
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$114K
3
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$43.5K
4
TRCT
Tower Research Capital (TRC)
New York
+$10.3K
5
UBS Group
UBS Group
Switzerland
+$6.34K

Top Sellers

Rank Fund Capital Flow
1
MFG
Merit Financial Group
Georgia
-$63K
2
VF
Virtu Financial
New York
-$33K
3
Two Sigma Investments
Two Sigma Investments
New York
-$12.4K
4
Citadel Advisors
Citadel Advisors
Florida
-$8.59K
5
Citigroup
Citigroup
New York
-$4K
Name Holding Trade Value Shares
Change 		Change in
Stake
ICM
1
Invenomic Capital Management
Massachusetts
$1.16M +$307K +107,891 +30%
Geode Capital Management
2
Geode Capital Management
Massachusetts
$120K -$2.63K -924 -2%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$98K +$114K +40,119 New
Vanguard Group
4
Vanguard Group
Pennsylvania
$81K -$2.73K -958 -3%
Citadel Advisors
5
Citadel Advisors
Florida
$61K -$8.59K -3,014 -11%
Dimensional Fund Advisors
6
Dimensional Fund Advisors
Texas
$37K +$43.5K +15,264 New
Two Sigma Investments
7
Two Sigma Investments
New York
$32K -$12.4K -4,338 -25%
CC
8
Centiva Capital
New York
$32K -$2.56K -900 -6%
Renaissance Technologies
9
Renaissance Technologies
New York
$29K +$1.14K +400 +3%
UBS Group
10
UBS Group
Switzerland
$16K +$6.34K +2,227 +53%
TRCT
11
Tower Research Capital (TRC)
New York
$9K +$10.3K +3,628 New
Osaic Holdings
12
Osaic Holdings
Arizona
$5K – – –
Wells Fargo
13
Wells Fargo
California
$2K +$6 +2 +0.2%
APC
14
Aspire Private Capital
North Carolina
$1K – – –
Royal Bank of Canada
15
Royal Bank of Canada
Ontario, Canada
$1K – – –
MFG
16
Merit Financial Group
Georgia
– -$63K -21,267 Closed
VF
17
Virtu Financial
New York
– -$33K -10,975 Closed
Citigroup
18
Citigroup
New York
– -$4K -1,230 Closed

LEXX Hedge Fund Activity: Q3 2022 in Review

16 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in Lexaria Bioscience (LEXX) for Q3 2022, worth a combined $1.68M — up 0.6% from $1.67M a quarter earlier.

Fund positioning in LEXX was balanced in Q3 2022: 3 funds opened new positions, 3 closed out, 4 added to existing stakes and 5 trimmed.

The largest buyer was Invenomic Capital Management, adding an estimated $307K. The largest seller was Merit Financial Group, exiting entirely with an estimated $63K sold.

  • 16 institutional investors held Lexaria Bioscience (LEXX) as of Q3 2022, unchanged from Q2 2022.
  • Funds reported $1.68M of Lexaria Bioscience stock for Q3 2022, up 0.6% quarter-over-quarter.
  • 3 funds opened new Lexaria Bioscience positions in Q3 2022 and 3 closed out, a net change of 0 holders.
  • The largest Lexaria Bioscience buyer in Q3 2022 was Invenomic Capital Management, an estimated $307K added.
  • The largest Lexaria Bioscience seller in Q3 2022 was Merit Financial Group, an estimated $63K sold.

Based on aggregated 13F filings for Q3 2022.